Lung Cancer Test Kit

There are two types of lung cancer: non-small cell lung cancer (NSCLC), which occurs at a frequency of 80–85%, and small cell lung cancer, which occurs at a frequency of 15–20%. The epidermal growth factor receptor (EGFR) is expressed on the surface of epidermal cells and possesses tyrosine kinase activity. EGFR overexpression is exclusively observed in NSCLC and has the potential to induce transition induction, tumor-induced neoangiogenesis, and cell proliferation, thereby affecting the signal transduction system in cells. The growth of cancer cells is effectively inhibited by the EGFR tyrosine kinase inhibitor (TKI), gefinitib (Iressa, AstraZenca) or erlotinib (Tarceba, Roche), resulting in the death of cancer cells and the suppression of new blood vessels in lung cancer tissue. In particular, the response rate of EGFR-TKIs is strongly correlated with certain specific mutations in the ATP-binding domain of the EGFR gene. Additionally, it has been reported that patients with NSCLC who have EGFR mutations exhibit a longer survival rate and are more effective in responding to EGFR-TKI. Consequently, the EGFR mutation is emerging as a critical prognostic biomarker for drug response. The efficient detection of the EGFR mutation is anticipated to be highly beneficial in the context of targeted therapy for the improvement of the survival rate of patients with lung cancer.FEATURES

High sensitivity and specificity, even with a small amount of DNA (1% LOD with 25 ng wild/mutant type mixed DNA)

A ready-to-use kit that is based on real-time PCRLimited duration (three hours or less)